Comorbidity among inpatients with dementia: a preliminary cross-sectional study in West China

Xiaoqiang Xiao1,2,3, Shunju Xiang4,5, Qingya Xu1,2,3

  • 1Department of Neuropsychology, Sichuan Academy of Medical Sciences and Sichuan People's Hospital, Chengdu, Sichuan, China.

Insights

Hospitalized patients with dementia have more comorbidities than those without dementia. Conditions like cerebral vascular disease, epilepsy, and depression significantly increase dementia risk, particularly in vascular dementia cases.

Area of Science:

  • Gerontology
  • Neurology
  • Internal Medicine

Background:

  • Dementia is a growing global health concern, often accompanied by multiple coexisting medical conditions (comorbidities).
  • Understanding these comorbidities is crucial for comprehensive patient care and management strategies.
  • Hospitalized dementia patients represent a significant population with complex health needs.

Purpose of the Study:

  • To investigate the prevalence and types of comorbidities in hospitalized patients diagnosed with dementia.
  • To compare comorbidity profiles between dementia patients and non-dementia controls.
  • To identify specific comorbidities associated with an increased risk of dementia, including Alzheimer's disease and vascular dementia.

Main Methods:

  • Retrospective analysis of discharge records from 3355 hospitalized patients.
  • Comorbidities identified using the Charlson Comorbidity Index (CCI) and Elixhauser Comorbidity Index (ECI) based on ICD-10 codes.
  • Logistic regression models used to determine associations between comorbidities and dementia, comparing dementia patients with matched controls and differentiating between Alzheimer's and vascular dementia.

Main Results:

  • Dementia patients (n=3355) exhibited a higher average number of comorbidities (3.8) compared to controls (2.9).
  • Prevalent comorbidities in dementia patients included cerebral vascular disease (73.0%), hypertension (62.8%), and peripheral vascular disease (53.7%).
  • Significant risk factors for dementia were epilepsy (OR 4.8), cerebral vascular disease (OR 4.1), and depression (OR 4.0). Vascular dementia showed a higher burden of cardiovascular and cerebrovascular comorbidities than Alzheimer's disease.

Conclusions:

  • Hospitalized patients with dementia have a significantly greater comorbidity burden than non-dementia patients.
  • Cardio-cerebral vascular diseases, epilepsy, diabetes, and depression are key comorbidities associated with increased dementia risk.
  • Vascular dementia patients present with more severe cardiovascular and cerebrovascular comorbidities compared to Alzheimer's disease patients.
Abstract

Related Concept Videos

Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
151
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
594
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
237